<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011425</article-id><article-id pub-id-type="publisher-id">ACM-38938</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_46335637.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  脂蛋白A与急性冠脉综合征预后的相关性分析
  Correlation between Lipoprotein A and Prognosis of Acute Coronary Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姬</surname><given-names>赞赞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>靖宇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>晴</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>喆</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>金</surname><given-names>睿杰</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院急诊科，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2799</fpage><lpage>2804</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨脂蛋白A对急性冠脉综合征(acute coronary syndrome, ACS)预后的相关性。方法：回顾性收集了自2016年6月~2020年6月青岛大学附属医院急性冠脉综合征患者391例，平均随访18月，将患者是否再次发生临床心脑血管不良事件分组。分别收集2组患者临床资料，对2组的年龄、性别、体指数、血压、血糖、血脂、Gensini评分等进行比较，采用单因素及多因素Logistic回归分析ACS预后的相关危险因素。同时使用Spearman相关性分析脂蛋白A与Gensini评分(冠脉血管严重程度)之间的关系。结果：脂蛋白A水平与冠脉血管严重程度有相关性(r = 0.119, P &lt; 0.05)。多因素Logistic回归分析校正混杂因素后显示，糖尿病、脂蛋白A为ACS患者再次发生临床心脑血管不良事件的独立危险因素(P &lt; 0.041 OR 1.1761 95%CI 1.023~3.034; P &lt; 0.002 OR 1.002 95%CI 1.001~1.003)。结论：脂蛋白A与冠脉血管狭窄程度呈正相关性，且脂蛋白A和糖尿病均是ACS预后不良的独立危险因素。
    Objective: To investigate the correlation of lipoprotein A with prognosis of acute coronary syndrome (ACS). Methods: A total of 391 patients with acute coronary syndrome from June 2016 to June 2020 in affiliated Hospital of Qingdao University were collected retrospectively. The mean follow-up was 18 months, and the patients were divided into groups whether they had clinical cardiovascular and cerebrovascular adverse events again. The clinical data of the 2 groups were collected, and the age, sex, body index, blood pressure, blood glucose, blood lipids, Gensini score of the 2 groups were compared. The risk factors related to the prognosis of ACS were analyzed by univariate and multivariate Logistic regression. Spearman correlation was also used to analyze the relationship between lipoprotein A and Gensini score (coronary artery severity). Results: Lipoprotein A level was correlated with coronary artery severity (R = 0.119, P &lt; 0.05). Multivariate Logistic regression analysis after adjusting showed that diabetes mellitus and lipoprotein A were independent risk factors for recurrent clinical cardiovascular and cerebrovascular adverse events in ACS patients (P &lt; 0.041 OR 1.1761 95%CI 1.023 - 3.034; P &lt; 0.002 OR 1.002 95%CI 1.001 - 1.003). Conclusion: Lipoprotein A is positively correlated with the degree of coronary artery stenosis, and both lipoprotein A and diabetes mellitus are independent risk factors for prognosis of ACS. 
  
 
</p></abstract><kwd-group><kwd>急性冠脉综合征，脂蛋白A，预后，心脑血管不良事件, Acute Coronary Syndrome</kwd><kwd> Lipoprotein A</kwd><kwd> Prognosis</kwd><kwd> Clinical Cardiovascular and Cerebrovascular Adverse Events</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨脂蛋白A对急性冠脉综合征(acute coronary syndrome, ACS)预后的相关性。方法：回顾性收集了自2016年6月~2020年6月青岛大学附属医院急性冠脉综合征患者391例，平均随访18月，将患者是否再次发生临床心脑血管不良事件分组。分别收集2组患者临床资料，对2组的年龄、性别、体指数、血压、血糖、血脂、Gensini评分等进行比较，采用单因素及多因素Logistic回归分析ACS预后的相关危险因素。同时使用Spearman相关性分析脂蛋白A与Gensini评分(冠脉血管严重程度)之间的关系。结果：脂蛋白A水平与冠脉血管严重程度有相关性(r = 0.119, P &lt; 0.05)。多因素Logistic回归分析校正混杂因素后显示，糖尿病、脂蛋白A为ACS患者再次发生临床心脑血管不良事件的独立危险因素(P &lt; 0.041 OR 1.1761 95%CI 1.023~3.034; P &lt; 0.002 OR 1.002 95%CI 1.001~1.003)。结论：脂蛋白A与冠脉血管狭窄程度呈正相关性，且脂蛋白A和糖尿病均是ACS预后不良的独立危险因素。</p></sec><sec id="s2"><title>关键词</title><p>急性冠脉综合征，脂蛋白A，预后，心脑血管不良事件</p></sec><sec id="s3"><title>Correlation between Lipoprotein A and Prognosis of Acute Coronary Syndrome<sup> </sup></title><p>Zanzan Ji, Peng Li<sup>*</sup>, Jingyu Song, Qing Liu, Zhe Li, Ruijie Jin</p><p>Emergency Department, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/59-1571709x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 23<sup>rd</sup>, 2020; published: Nov. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/59-1571709x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the correlation of lipoprotein A with prognosis of acute coronary syndrome (ACS). Methods: A total of 391 patients with acute coronary syndrome from June 2016 to June 2020 in affiliated Hospital of Qingdao University were collected retrospectively. The mean follow-up was 18 months, and the patients were divided into groups whether they had clinical cardiovascular and cerebrovascular adverse events again. The clinical data of the 2 groups were collected, and the age, sex, body index, blood pressure, blood glucose, blood lipids, Gensini score of the 2 groups were compared. The risk factors related to the prognosis of ACS were analyzed by univariate and multivariate Logistic regression. Spearman correlation was also used to analyze the relationship between lipoprotein A and Gensini score (coronary artery severity). Results: Lipoprotein A level was correlated with coronary artery severity (R = 0.119, P &lt; 0.05). Multivariate Logistic regression analysis after adjusting showed that diabetes mellitus and lipoprotein A were independent risk factors for recurrent clinical cardiovascular and cerebrovascular adverse events in ACS patients (P &lt; 0.041 OR 1.1761 95%CI 1.023 - 3.034; P &lt; 0.002 OR 1.002 95%CI 1.001 - 1.003). Conclusion: Lipoprotein A is positively correlated with the degree of coronary artery stenosis, and both lipoprotein A and diabetes mellitus are independent risk factors for prognosis of ACS.</p><p>Keywords:Acute Coronary Syndrome, Lipoprotein A, Prognosis, Clinical Cardiovascular and Cerebrovascular Adverse Events</p><disp-formula id="hanspub.38938-formula45"><graphic xlink:href="//html.hanspub.org/file/59-1571709x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/59-1571709x8_hanspub.png" /> <img src="//html.hanspub.org/file/59-1571709x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性冠脉综合征(ACS)是指冠状动脉内不稳定的粥样斑块破裂或糜烂继发新鲜血栓形成所导致的心脏急性缺血综合征，涵盖了ST段抬高型心肌梗死(ST-segment elevation myocardial infarction, STEMI)、非ST段抬高型心肌梗死(Non-ST-segment elevation myocardial infarction, NSTEMI)和不稳定型心绞痛(unstable angina, UA)。并且ACS的发病率依然呈较高水平。给家庭和社会带来了很大的经济负担。目前对ACS治疗已得到很大的提升，例如：冠脉血管支架植入术、冠脉血管搭桥术等治疗方案，大大提高了死亡率，但目前对ACS的预后预防的工作，还有些薄弱。血脂紊乱是ACS高危因素之一，人们对低密度脂蛋白胆固醇尤其重视，但近期对脂蛋白a的认知也在不断更新，有研究表示，脂蛋白a是动脉粥样硬化性心血管疾病(ASCVD)的独立危险因子，它的机制可能有促动脉粥样硬化、促血栓形成和抗纤维蛋白溶解等作用 [<xref ref-type="bibr" rid="hanspub.38938-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref2">2</xref>]。它在很久之前也得到很多研究的证实 [<xref ref-type="bibr" rid="hanspub.38938-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref5">5</xref>]。本研究想进一步探究脂蛋白a与ACS患者预后的相关性，并分析其危险因素；同时探索脂蛋白a与冠脉血管严重程度之间的关系。</p></sec><sec id="s6"><title>2. 材料和方法</title><p>1) 对象</p><p>回顾性选择2016年6月至2020年6月青岛大学附属医院患者共391例ACS患者，入选者参考2014年美国心脏病学院/美国心脏病协会(ACC/AHA)指南 [<xref ref-type="bibr" rid="hanspub.38938-ref6">6</xref>]。排除标准：严重肝肾功能障碍、恶性肿瘤、严重感染、自身免疫性疾病等患者。依是否再次发生心脑血管不良事件分2组。未再发生心脑血管事件为1组(286例)，再发生心脑血管事件为2组(105例)。本研究经医院伦理委员会批准，均知情签署同意书。</p><p>2) 方法</p><p>收集2组患者的性别、年龄、BMI、吸烟、饮酒、Gensini评分、高血压、糖尿病及血脂等临床资料。高血压患者纳入标准：收缩压 ≥ 140 mmHg，和/或舒张压 ≥ 90 mmHg；糖尿病诊断，参考美国糖尿病协会(ADA)和欧洲糖尿病研究协会(EASD)的共识 [<xref ref-type="bibr" rid="hanspub.38938-ref7">7</xref>]。通过冠脉血管造影进行Gensini评分，评分标准为：对每支冠状动脉病变狭窄程度进行定量评定，首先根据冠脉狭窄程度确定基本评分，狭窄直径 &lt; 25%计1+分，≥25%~&lt;50%计2+分，≥50%~&lt;75%计4+分，≥75%~&lt;90%计8+分，≥90%~&lt;99%计l6+分，99%~100%计32+分，再根据不同冠脉分支确定相应系数，分别为：左主干(LM)病变 &#215; 5；左前降支(LAD)病变：近段 &#215; 2.5，中段 &#215; 1.5，远段 &#215; 1；对角支病变：D1 &#215; 1，D2 &#215; 0.5；左回旋支(LCX)病变：近段 &#215; 2.5，钝缘支 &#215; 1，远段 &#215; 1，后降支 &#215; 1，后侧支 &#215; 0.5；右冠状动脉(RCA)病变：近、中、远和后降支均 &#215; 1。采集入院24 h内清晨空腹外周静脉血，进行血浆总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)脂蛋白a等的检测。</p><p>再次发生心脑血管不良事件(MACCE)，又称再发不良事件，包括：再发心绞痛、再发心肌梗死、急性心力衰竭、缺血性脑血管疾病、心源性或脑源性死亡。</p><p>3) 统计学</p><p>采用SSPS 25.0软件进行统计学分析。计量资料使用平均数、标准差等表示；分类变量用百分数表示；计数资料组间比较采用卡方检验；Spearman相关性分析脂蛋白a与Gensini评分(冠脉血管严重程度)的相关性；采用单因素及多因素Logistic回归分析法分析ACS患者再发心脑血管不良事件的相关危险因素。P &lt; 0.05为差异有统计学意义。</p></sec><sec id="s7"><title>3. 结果</title><p>1) 两组患者临床资料和血脂水平如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline data of patients in both group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男性 (例，%)</th><th align="center" valign="middle" >年龄 (岁，x &#177; s)</th><th align="center" valign="middle" >BMI (kg/m<sup>2</sup>，x &#177; s)</th><th align="center" valign="middle" >吸烟 (例，%)</th><th align="center" valign="middle" >饮酒 (例，%)</th><th align="center" valign="middle" >高血压 (例，%)</th><th align="center" valign="middle" >糖尿病 (例，%)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >286</td><td align="center" valign="middle" >219 (76.6)</td><td align="center" valign="middle" >60 &#177; 12.0</td><td align="center" valign="middle" >25.0 &#177; 3.1</td><td align="center" valign="middle" >174 (60.8)</td><td align="center" valign="middle" >191 (66.8)</td><td align="center" valign="middle" >123 (43.0)</td><td align="center" valign="middle" >226 (79)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >105</td><td align="center" valign="middle" >76 (72.4)</td><td align="center" valign="middle" >62 &#177; 10.7</td><td align="center" valign="middle" >25.4 &#177; 3.6</td><td align="center" valign="middle" >68 (64.8)</td><td align="center" valign="middle" >77 (73.3)</td><td align="center" valign="middle" >36 (34.3)</td><td align="center" valign="middle" >71 (67.6)</td></tr></tbody></table></table-wrap><p>表1. 2组患者基线资料</p><p>1：无再发心脑血管不良事件组；2：再发心脑血管不良事件组；TG：甘油三酯；TC：总胆固醇；HDL-C：高密度脂蛋白胆固醇；LDL-C：低密度脂蛋白胆固醇；Lp[a]：脂蛋白a。</p><p>2) 脂蛋白a与冠脉血管严重程度(Gensini评分)之间的关系。</p><p>如表2所示，将脂蛋白a与冠脉血管严重程度(Gensini评分)进行相关性分析，结果显示：P = 0.027，也就是说脂蛋白a水平与冠脉血管狭窄程度成线性关系。脂蛋白a水平较高的患者，冠脉血管狭窄程度越严重。可作为临床预测指标，预示患者的不良的冠脉血管情况。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Correlation between serum lipoprotein a and Gensini scor</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="3"  ></th><th align="center" valign="middle" >Lp-a (mg/L)</th><th align="center" valign="middle" >gensini评分</th></tr></thead><tr><td align="center" valign="middle"  rowspan="4"  >斯皮尔曼 Rho</td><td align="center" valign="middle"  rowspan="2"  >Lp-a (mg/L)</td><td align="center" valign="middle" >相关系数</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >R = 0.119<sup>*</sup></td></tr><tr><td align="center" valign="middle" >Sig. (双尾)</td><td align="center" valign="middle" >.</td><td align="center" valign="middle" >P = 0.027</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >gensini评分</td><td align="center" valign="middle" >相关系数</td><td align="center" valign="middle" >0.119<sup>*</sup></td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >Sig. (双尾)</td><td align="center" valign="middle" >0.027</td><td align="center" valign="middle" >.</td></tr></tbody></table></table-wrap><p>表2. 血清脂蛋白a与Gensini评分的相关性结果</p><p>P在0.05级别(双尾)，相关性显著。</p><p>3) ACS患者再发不良事件的相关危险因素的多因素Logistic回归分析</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Multivariate logistic regression analysis of risk factors associated with poor prognosis of acute coronary syndrom</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  rowspan="2"  >B</th><th align="center" valign="middle"  rowspan="2"  >标准误差</th><th align="center" valign="middle"  rowspan="2"  >Ward值</th><th align="center" valign="middle"  rowspan="2"  >自由度</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  rowspan="2"  >OR</th><th align="center" valign="middle"  colspan="2"  >95%置信区间</th></tr></thead><tr><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >0.012</td><td align="center" valign="middle" >3.087</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.079</td><td align="center" valign="middle" >1.021</td><td align="center" valign="middle" >0.998</td><td align="center" valign="middle" >1.045</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >0.566</td><td align="center" valign="middle" >0.277</td><td align="center" valign="middle" >4.165</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.041</td><td align="center" valign="middle" >1.761</td><td align="center" valign="middle" >1.023</td><td align="center" valign="middle" >3.034</td></tr><tr><td align="center" valign="middle" >酒</td><td align="center" valign="middle" >−0.284</td><td align="center" valign="middle" >0.282</td><td align="center" valign="middle" >1.020</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.312</td><td align="center" valign="middle" >0.752</td><td align="center" valign="middle" >0.433</td><td align="center" valign="middle" >1.307</td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >0.249</td><td align="center" valign="middle" >0.263</td><td align="center" valign="middle" >0.893</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.345</td><td align="center" valign="middle" >1.282</td><td align="center" valign="middle" >0.766</td><td align="center" valign="middle" >2.147</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >−0.125</td><td align="center" valign="middle" >0.127</td><td align="center" valign="middle" >0.965</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.326</td><td align="center" valign="middle" >0.883</td><td align="center" valign="middle" >0.688</td><td align="center" valign="middle" >1.132</td></tr><tr><td align="center" valign="middle" >Lp-a (mg/L)</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >9.688</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >1.002</td><td align="center" valign="middle" >1.001</td><td align="center" valign="middle" >1.003</td></tr></tbody></table></table-wrap><p>表3. 急性冠脉综合征不良预后的相关危险因素的多因素Logistic回归分析</p><p>TG是甘油三酯；Lp-a是脂蛋白a；OR是比值比；B是回归系数。</p><p>在校正混杂因素以后显示，重新对年龄、糖尿病史、饮酒史、高血压史、甘油三酯、脂蛋白a水平进行多因素分析，如表3，结果显示：糖尿病、脂蛋白a (P &lt; 0.041 OR 1.1761 95%CI 1.023~3.034；P &lt; 0.002 OR 1.002 95%CI 1.001~1.003)，糖尿病史、脂蛋白a水平与再次发生临床心脑不良事件之间差异性有统计学意义，换言之，脂蛋白a水平和患者有无糖尿病史均为ACS患者再发不良事件的独立危险因素。这与以往研究结果是一致的。</p></sec><sec id="s8"><title>4. 讨论</title><p>脂蛋白a是由类低密度脂蛋白胆固醇颗粒和载脂蛋白a[apo(a)]组成的一类脂质，它被大家所知已久，但仍有很多未解之处，它的生理代谢、检测等都有待进一步研究。由孟德尔随机定律得知，脂蛋白a是有基因遗传倾向的，几乎不受饮食、生活方式等因素的改变，并且对于人群的风险预测以及风险分层可以提供有用的线索 [<xref ref-type="bibr" rid="hanspub.38938-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref9">9</xref>]。再次被大家热议，基于近年来有大量的国内外研究发现，脂蛋白a不仅是冠状动脉粥样硬化性心脏病、脑卒中的独立危险因素，同时也在家族性高脂血症、钙化性主动脉狭窄、冠脉血管疾病(CVD)、颈动脉斑块形成等疾病中具有重要作用。另外有个案报道研究发现血清脂蛋白a的异常高水平可能影响年轻成年患者的系统性动脉粥样硬化以及心肌梗塞的发作 [<xref ref-type="bibr" rid="hanspub.38938-ref10">10</xref>]。所以，对于脂蛋白a，我们应该逐渐加以重视。有研究显示脂蛋白a是CVD患者的残余风险 [<xref ref-type="bibr" rid="hanspub.38938-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref12">12</xref>]，在经过积极控制CVD高危因素，尤其低密度脂蛋白胆固醇水平，仍有不良事件发生，但此结论仍有争议。这可能与LDL-C和脂蛋白a之间生理结构相似性有关。下一步可研究在低密度脂蛋白胆固醇在降到目标值后，脂蛋白a与ASCVD残余风险之间的关系。</p><p>脂蛋白a水平在种族之间有明显的差异。非洲等黑色人种具有较高水平，而北美等白色人种脂蛋白a水平则相对较低，这可能与载脂蛋白a的高度多态性有关 [<xref ref-type="bibr" rid="hanspub.38938-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref14">14</xref>]。它的基因决定性，也是脂蛋白a在国际上未达到同一标准的原因所在。所以，各个国家/国际协会会有不用的指南 [<xref ref-type="bibr" rid="hanspub.38938-ref15">15</xref>]。同时，脂蛋白a的水平也与不同的疾病、严重程度等也有关系 [<xref ref-type="bibr" rid="hanspub.38938-ref16">16</xref>]。Kang. H等 [<xref ref-type="bibr" rid="hanspub.38938-ref17">17</xref>] 研究表示，脂蛋白a可促进钙化性主动脉狭窄；Daniel T等 [<xref ref-type="bibr" rid="hanspub.38938-ref18">18</xref>] 证实，脂蛋白(a)是杂合子家族性高胆固醇血症中心血管疾病的独立危险因素。而且，它的分级(脂蛋白a ≥ 300 mg/l)在临床诊疗中也有一定指导作用。有研究证明，在脂蛋白a ≥ 300 mg/l时，患者发生心血管事件的可能性更高，总的来说，当脂蛋白a ≥ 300 mg/l时，发生MACE的可能性要高1.2倍(95% CI 1.1, 1.4, P = 0.005)，发生冠状动脉重建的可能性要高1.2倍(95% CI 1.0, 1.4, P = 0.02) [<xref ref-type="bibr" rid="hanspub.38938-ref3">3</xref>]。以上都说明了脂蛋白a对心血管疾病的发生起到了很大的作用，对其水平的控制也在逐渐增强。</p><p>本研究证实了基线脂蛋白a水平与冠脉血管严重程度是成正相关的，这与之前的研究也是一致的 [<xref ref-type="bibr" rid="hanspub.38938-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38938-ref21">21</xref>]。基线脂蛋白a水平较高，可能也代表了患者的冠脉血管狭窄较重。另外，本试验证实了基线脂蛋白a水平是ACS患者预后的独立危险因素，换而言之，在已发生心血管疾病的患者中，他的基线高脂蛋白a在一定程度上决定了他的预后，不管低密度脂蛋白胆固醇水平如何。它预示了心血管疾病再发率的可能性。这一研究更加证明了脂蛋白a在临床的重大作用，它对ACS患者不良预后有很大的指导意义。另外，糖尿病同时也被证明，它对已发生心血管疾病患者的不良预后有很大的预测作用。因此，对于已患有CVD同时合并糖尿病的患者，需要更加注重其血糖的控制，可减少再发不良事件的发生率。总而言之，在ACS患者中，合并糖尿病，还有高脂蛋白a水平时，可能预示患者再次发生心脑血管事件的机率很大，预后极差。因此，本研究提示了我们在之后的临床工作中，应加大对血糖的管理，也要更加关注脂蛋白a水平。下一步可研究特异性降脂蛋白a之后，对临床的效益。</p></sec><sec id="s9"><title>文章引用</title><p>姬赞赞,李 鹏,宋靖宇,刘 晴,李 喆,金睿杰. 脂蛋白A与急性冠脉综合征预后的相关性分析Correlation between Lipoprotein A and Prognosis of Acute Coronary Syndrome[J]. 临床医学进展, 2020, 10(11): 2799-2804. https://doi.org/10.12677/ACM.2020.1011425</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38938-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rawther, T. and Tabet, F. (2019) Biology, Pathophysiology and Current Therapies That Affect Lipoprotein (a) Levels. The Journal of Molecular and Cellular Cardiology, 131, 1-11. &lt;br&gt;https://doi.org/10.1016/j.yjmcc.2019.04.005</mixed-citation></ref><ref id="hanspub.38938-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Labudovic, D., Kostovska, I., Trajkovska, K.T., et al. (2019) Lipoprotein(a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. &lt;br&gt;https://doi.org/10.14712/23362936.2019.9</mixed-citation></ref><ref id="hanspub.38938-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Nicholls, S.J., Tang, W.H.W., Scoffone, H., et al. (2010) Lipoprotein(a) Levels and Long-Term Cardiovascular Risk in the Contemporary Era of Statin Therapy. Journal of Lipid Research, 51, 3055-3061.  
&lt;br&gt;https://doi.org/10.1194/jlr.M008961</mixed-citation></ref><ref id="hanspub.38938-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Danesh, J., Collins, R. and Peto, R. (2000) Lipoprotein(a) and Coronary Heart Disease. Meta-Analysis of Prospective Studies. Circulation, 102, 1082-1085. &lt;br&gt;https://doi.org/10.1161/01.CIR.102.10.1082</mixed-citation></ref><ref id="hanspub.38938-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rifai, N., Ma, J., Sacks, F.M, et al. (2004) Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians’ Health Study. Clinical Chemistry, 50 1364-1371. &lt;br&gt;https://doi.org/10.1373/clinchem.2003.030031</mixed-citation></ref><ref id="hanspub.38938-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64, e139-e228.</mixed-citation></ref><ref id="hanspub.38938-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Giaccari, A. and Inzucchi, S.E., for the ADA/EASD Position Statement Group (2012) Comment on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-1379. Diabetes Care, 35, e72-e73. &lt;br&gt;https://doi.org/10.2337/dc12-1184</mixed-citation></ref><ref id="hanspub.38938-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zekavat, S.M., Ruotsalainen, S., Handsaker, R.E., et al. (2018) Deep Coverage Whole Genome Sequences and Plasma Lipoprotein(a) in Individuals of European and African Ancestries. Nature Communications, 9, Article No. 2606.  
&lt;br&gt;https://doi.org/10.1038/s41467-018-04668-w</mixed-citation></ref><ref id="hanspub.38938-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tada, H., Kawashiri, M.A. and Yamagishi, M. (2017) Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 24, 452-461.  
&lt;br&gt;https://doi.org/10.5551/jat.RV17002</mixed-citation></ref><ref id="hanspub.38938-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hiraiwa, H., Morimoto, R., Okumura, T., et al. (2019) A Survival Case of a Young Adult Patient with ST-Elevated Myocardial Infarction with High levels of Lipoprotein(a). Journal of Cardiology Cases, 19, 207-210.  
&lt;br&gt;https://doi.org/10.1016/j.jccase.2019.02.004</mixed-citation></ref><ref id="hanspub.38938-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Khera, A.V., Everett, B.M., Caulfield, M.P., et al. (2014) Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 129, 635-642.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.113.004406</mixed-citation></ref><ref id="hanspub.38938-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">宋佳希, 汪俊军. 关注非传统危险因子在心血管疾病残余风险评估中的作用[J]. 中华检验医学杂志, 2019(8): 595-601.</mixed-citation></ref><ref id="hanspub.38938-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, K., Noureen, A. and Kronenberg, F. (2016) Structure, Function, and Genetics of Lipoprotein (a). Journal of Lipid Research, 57, 1339-1359. &lt;br&gt;https://doi.org/10.1194/jlr.R067314</mixed-citation></ref><ref id="hanspub.38938-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Enas, E.A., Varkey, B., Dharmarajan, T.S., et al. (2019) Lipoprotein(a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112.  
&lt;br&gt;https://doi.org/10.1016/j.ihj.2019.03.004</mixed-citation></ref><ref id="hanspub.38938-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yoshida, H. (2019) Clinical Impact and Significance of Serum Lipoprotein (a) Levels on Cardiovascular Risk in Patients with Coronary Artery Disease. Circulation Journal, 83, 967-968. &lt;br&gt;https://doi.org/10.1253/circj.CJ-19-0221</mixed-citation></ref><ref id="hanspub.38938-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ellis, K.L., Chakraborty, A., Moses, E.K. and Watts, G.F. (2019) To Test, or Not to Test: That Is the Question for the Future of Lipoprotein(a). Expert Review of Cardiovascular Therapy, 17, 241-250.  
&lt;br&gt;https://doi.org/10.1080/14779072.2019.1596799</mixed-citation></ref><ref id="hanspub.38938-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. Journal of the American College of Cardiology, 73, 2150-2162.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2019.01.070</mixed-citation></ref><ref id="hanspub.38938-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Holmes, D.T., Schick, B.A., Humphries, K.H. and Frohlich, J. (2005) Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia. Clinical Chemistry, 51, 2067-2073.  
&lt;br&gt;https://doi.org/10.1373/clinchem.2005.055228</mixed-citation></ref><ref id="hanspub.38938-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, B.-Y., Sun, D., Wang, C., et al. (2019) Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart, Lung and Circulation, 28, 1009-1017. &lt;br&gt;https://doi.org/10.1016/j.hlc.2018.05.190</mixed-citation></ref><ref id="hanspub.38938-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">谷阳, 于昆, 徐琢, 葛培兵, 张喜文. 脂蛋白(a)对非ST段抬高型急性冠状动脉综合征患者风险评估的价值[J]. 中华老年心脑血管病杂志, 2018, 20(2): 149-152.</mixed-citation></ref><ref id="hanspub.38938-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">马煜盛. 脂蛋白(a)与冠心病风险及严重程度关系的研究[D]: [博士学位论文]. 广州: 南方医科大学, 2019.</mixed-citation></ref></ref-list></back></article>